Neurology

A new study published in Nature Communications used artificial intelligence (AI) to identify 3 new multiple sclerosis (MS) subtypes, which may help identify which individuals are more likely to have disease progression, according to the authors.

April is Parkinson’s Awareness Month, so what better time to refresh your understanding and promote awareness around Parkinson disease than now?

Nine in 10 patients with multiple sclerosis who received the medication did not have worsening of 3-month disability, and ponesimod showed a numerical benefit in delaying disability progression.

Additionally, the study revealed for the first time the physiological reason for the neutral protection is increased blood flow to the brain as a result of higher levels of progesterone.

The study compared step impairments across the cognitive spectrum, including people with subjective cognitive impairment, Parkinson disease, mild cognitive impairment, Alzheimer disease, Lewy body dementia, and frontotemporal dementia, as well as cognitively healthy controls.

The investigators also found significant racial disparities, with Black patients with dementia more likely to be infected with COVID-19 than white patients with dementia.

Some OTC nonsteroidal anti-inflammatory drugs or combination analgesics can be used to treat migraine in children.

Patients with multiple sclerosis who rely on family members as caregivers may be at particular risk for mistreatment, as those caregivers struggle to balance work, childcare, and health concerns of their own.

The product portfolio includes lamotrigine (ET-105), zonisamide (ET-104), and topiramate (ET-101). These medications are currently under review with the FDA.

Migraine attacks are the leading cause of disability in individuals younger than 50 years and predominantly affect women.

The diagnosis and management of neurologic conditions can be more complex when patients are at the extremes of age.

The new administration option for multiple sclerosis treatment could improve access during the COVID-19 pandemic, when availability has been a concern.

As care improves, cognitive impairment is likely to be seen earlier in patients with coronary artery disease, diabetes, and HIV.

Because there are multiple sources for concussion-like symptoms, student-athletes’ post-concussion care should zero in on which symptoms are specifically caused by the injury and which may be caused by other issues.

Studies have shown that patients with Parkinson disease admitted to the hospital experience longer hospital stays and increased mortality than age matched control groups.

Amantadine, a treatment that was originally used as an agent against influenza A, lost efficacy due to viral resistance.

The approach is being developed specifically as a potential treatment for the significant fraction of people with debilitating depression who do not respond to existing therapies and are at high risk of suicide.

The increased risk may be due to changes in the brain’s dopamine system caused by dopamine receptor antagonists or neurobiological effects of schizophrenia.

The symptoms of depression in caregivers of patients with dementia exacerbates over time.

COVID-19 has been found in the brain post-mortem.

Without coordinated care to ensure proper adherence, the resulting costs can become downright staggering for health systems.

Although cytokine storms are usually associated with severe COVID-19, study indicates less severe disease may also be at risk of cytokine storm.

Delirium is a common syndrome experienced by patients with COVID-19 while being treated in the ICU, according to a session at the 2020 ASHP Midyear Clinical Meeting and Exhibition.

The tau protein can help identify Alzheimer disease before cognitive decline begins.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week

The treatment of mental illness has long been a quandary for medical professionals throughout history. But historically, mental illness has been more loosely defined than it is today.

Compared with patients with focal epilepsy, those with genialized epilepsy have a higher risk of obstructive sleep apnea.

A final vote that assessed whether the findings from the EMERGE trial served as primary evidence for the efficacy of aducanumab in Alzheimer disease was 10–0 that the trial did not provide evidence.

The current acute treatments for migraines have shown efficacy and safety, however, approximately one-third of people do not respond, cannot use these options due to contraindications, or report dissatisfaction in therapy.

Simple sugar found in breast milk and dietary supplements may promote myelin repair in patients with multiple sclerosis.